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Abstract: Apoptosis is a programmed cell death that plays a critical role in cell 
homeostasis. In particular, apoptosis in cardiomyocytes is involved in several 
cardiovascular diseases including heart failure. Recently autophagy has emerged as an 
important modulator of programmed cell death pathway. Recent evidence indicates that 
saturated fatty acids induce cell death through apoptosis and this effect is specific for 
palmitate. On the other hand, n-3 polyunsaturated fatty acids (PUFAs) have been 
implicated in the protection against cardiovascular diseases, cardiac ischemic damage and 
myocardial dysfunction. In the present study we show that n-3 PUFA eicosapentaenoic 
acid (EPA) treatment to culture medium of H9c2 rat cardiomyoblasts protects cells against 
palmitate-induced apoptosis, as well as counteracts palmitate-mediated increase of 
autophagy. Further investigation is required to establish whether the antiautophagic effect 
of EPA may be involved in its cytoprotective outcome and to explore the underlying 
biochemical mechanisms through which palmitate and EPA control the fate of cardiac cells. 
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1. Introduction 
It is universally recognized that the quality and quantity of dietary fat ingested may contribute to the 
onset and progression of several chronic diseases impacting human health. Excessive levels of dietary 
saturated fatty acids or an imbalance of saturated versus unsaturated fats have been implicated in the 
pathogenesis of diabetes, obesity, atherosclerosis and cardiovascular diseases [1]. High fat feeding 
increases fat mass, elevates plasma free fatty acid levels and suppresses insulin signaling [2]. Elevated 
plasma levels of fatty acids represent a risk factor for coronary artery disease and cardiac dysfunction. 
Moreover, accumulation of saturated fatty acids in the heart has been involved in the development of 
heart failure and cardiomyopathy [3,4]. 
On the other hand, long chain n-3 polyunsaturated fatty acids (PUFAs), in which the first double 
bond is located between carbon 3 and 4, counting from methyl end (omega or n) of the carbon chain, 
proved to exert beneficial effects on the cardiovascular system. Overall research indicated that the 
consumption of seafood or marine-derived (eicosapentaenoic acid, EPA; docosahexaenoic acid, DHA) 
n-3 PUFAs reduces coronary heart disease mortality in populations with or without established 
cardiovascular diseases [5]. Recent studies have shown that n-3 PUFA can prevent myocardial tissue 
derangement in hypertrophic cardiomyopathic hamsters improving heart function and dramatically 
extending the cardiomyopathic animal longevity [6]. Nonetheless, the mechanisms through which   
n-3 PUFA beneficial effects on the cardiac tissues occur remain largely unknown. In response to 
pathophysiological stresses, cardiac myocytes undergo hypertrophic growth and/or apoptosis, which 
are associated to the development of cardiac pathologies. Accumulating evidence from in vivo and  
in vitro studies strongly suggests that apoptosis may play an important role in the pathogenesis of 
several cardiovascular diseases, such as ischemia/reperfusion, infarction, heart failure and aging [7]. 
It has recently become clear that different naturally occurring dietary fatty acids are able to 
modulate the molecular pathways involved in apoptosis. Palmitic acid has been implicated in the 
induction of apoptosis in different cell types, including neonatal cardiomyocytes. In these cells EPA 
supplementation is able to modulate gene expression [8] and elicits a protective effect against 
apoptosis induced by saturated fatty acid [9]. 
Recent studies have shown that autophagy modulates whether cardiomyocytes go towards survival 
or cell death. Autophagy is a catabolic process whereby cells respond to energy stress by degrading 
and recycling damaged proteins and intracellular components: ribosomes, lipids and even entire 
organelles [10,11]. Physiologically, autophagy functions as a quality control of cellular milieu, 
however, dysregulation of autophagy is implicated in a wide variety of pathological conditions and can 
lead to cell death [12,13]. Autophagy plays a role in the pathogenesis of a number of human diseases, 
and conditions including obesity and steatosis [14]. It is however unknown what factor or factors 
determine whether autophagy will be protective or detrimental to the cell, it is likely that the level and 
duration of autophagy are important. 
A complex interrelationship seems to exist between autophagy and the apoptotic cell death. The 
cross-talk between the two processes is sometimes contradictory, but surely critical to the overall fate 
of the cell (reviewed in ref. [15]). Recently autophagy has been proposed as a novel mechanism 
involved in the protective action of resveratrol, a nutritional factor [16]. However to our knowledge, no Nutrients 2012, 4  80 
 
 
evidence is available regarding the influence of other cardioprotective nutrients, such as PUFAs,   
on autophagy.  
In the present study we have evaluated the effect of palmitic acid and EPA on the induction of cell 
death and autophagy in cardiac cells. We have found that palmitic acid (at concentrations normally 
found in plasma during fasting conditions) induces both autophagy and cell death by apoptosis, 
whereas EPA exerts a clear protective effect against palmitate toxicity. 
2. Experimental Section 
2.1. Materials 
Monoclonal anti-microtubule-associated protein 1A/1B-light chain 3 (LC3) and anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and secondary anti-rabbit antibodies were purchased from Cell 
Signaling Technology. Enhanced chemiluminescence (ECL) detection system was provided by GE 
Healthcare. DNA breaks detection was performed using the DeadEnd™ Assays obtained from 
Promega. All other chemicals were from Sigma Aldrich. 
2.2. Cell Cultures  
H9c2 embryonal rat-heart derived cells were cultured in Dulbecco’s Modified Eagle Medium 
supplemented with 10% heat inactivated fetal bovine serum, 100 IU/mL penicillin and 0.1 µg/mL 
streptomycin. For experiments, subcultured cells were grown for 48 h, than fresh medium was supplied 
with or without fatty acid addition.  
2.3. Fatty Acid Supplementation 
Palmitate 5 mM stock solution was prepared with 10% fatty acid-free albumin from bovine serum 
(BSA) and 5% ethanol. 10 mM EPA stock solution in absolute ethanol was mixed with 150 µM BSA, 
and the final concentrations in the medium were 60 µM EPA and 30 µM BSA. Control cells were 
treated with the same BSA and ethanol solutions without palmitate or EPA.  
2.4. Cell Viability 
Evaluation of viable cells in our experimental protocol was performed by two different methods: the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and Trypan Blue exclusion 
test. The first is a colorimetric method based on the ability of viable cells to reduce MTT from a 
yellow water-soluble dye to a dark blue insoluble formazan product [17]. The Trypan Blue exclusion 
method is based on the count with a Burker hemocytometer of both living cells and stained dead cells. 
Dead cells were reported as a percentage of the total number of cells.  
2.5. Determination of Caspase Activity  
Caspase activity was measured by the cleavage of the fluorogenic peptide   
Ac-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC), which represents a substrate   
for caspase-3 and other effector caspases, as previously described [18,19].  Nutrients 2012, 4  81 
 
 
2.6. DNA Breaks Detection by in Situ-Labeling and Nuclear Staining 
To label apoptotic nuclei, the 3′-OH end of DNA fragments was visualized by the method of 
terminal transferase-mediated dUTP nick end-labeling (TUNEL). The nuclei of apoptotic and   
non-apoptotic cells were counterstained with 0.1 μg/mL 4′,6-diamidino-2-phenylindole (DAPI). The 
labeled cells were analyzed by fluorescence microscopy. The percentage of apoptotic cells was 
calculated as the ratio of the number of TUNEL-positive cells to the total number of DAPI-stained 
cells, counted in three different random fields. 
2.7. Immunoblot Analysis 
The proteins were detected in cell extracts by Western blotting: equal amounts of cell extract were 
subjected to electrophoresis in 15% gels, blotted onto nitrocellulose membranes as described [20], and 
probed with anti-LC3 antibody or anti-GAPDH antibody at 4 °C overnight. After washes, membranes 
were incubated with horseradish peroxidase-conjugated anti-rabbit IgG for 1 h. The chemiluminescent 
signals were detected using an ECL system. GAPDH was used as loading control. A representative 
image of visualized immunoreactive bands and densitometric analysis show the relative intensity of 
LC3-II expression. 
2.8. Statistical Analysis 
All the data presented as graphs are expressed as means ± SEM of the indicated numbers of 
determinations, and analyzed for statistical significance by one-way or two-way ANOVA. Differences 
were considered significant for P < 0.05. 
3. Results  
3.1. Palmitate Induces Cell Death in H9c2: Effect of EPA 
In order to determine the effects of saturated fatty acids on myocardial cells, we first tested the 
viability of H9c2 cardiomyoblasts treated with increasing doses of palmitate.  
Figure 1 shows that under control conditions, palmitate (50–500 µM) significantly and   
time-dependently decreased cell viability, assessed by the MTT reduction assay. Since palmitate was 
most effective in reducing the cell viability at the dose of 500 µM, we used this concentration in all 
subsequent experiments. 
The palmitate-mediated reduction of cell viability was also confirmed by Trypan Blue exclusion 
test (Figure 2a). In particular, after a 24 h treatment with palmitate, the number of cells that included 
Trypan Blue increased to about 30% of total cells compared to 10% of control. 
Long chain PUFAs play an important role in cardioprotection. These effects have been largely 
attributed to membrane DHA. Unlike DHA, EPA does not significantly enter cardiac membranes   
in vivo [21] and its beneficial effects have been often attributed to an acute effect [22].  
In our experimental conditions a protective effect of EPA on palmitate reduction of H9c2 viability 
was observable when the polyunsaturated fatty acid was added to the cells together with palmitate. In Nutrients 2012, 4  82 
 
 
fact, Figure 2a shows that while the treatment of H9c2 cardiomyoblasts with 60 µM EPA did not affect 
cell survival in control conditions, it significantly reduced cell death in palmitate-treated cultures.  
The protective effect of EPA is also depicted in the pictures in Figure 2b which shows that EPA 
attenuated the palmitate increase in cell death. The pro-survival effect of EPA was particularly evident 
when 500 µM palmitate was used to induce cell death.  
Figure 1. Effect of palmitate on H9c2 cardiomyoblasts viability. H9c2 cells were 
incubated for the indicated times under control conditions (CTRL) or increasing 
concentrations of palmitate (PALM). Results are means ± SEM. **  P < 0.005;   
*** P < 0.001. 
 
Figure 2. Effect of eicosapentaenoic acid (EPA) on survival of H9c2 exposed to palmitate. 
(a) The survival of cells exposed to 500 µM palmitate in the presence or absence of 60 μM 
EPA was measured by Trypan Blue exclusion. Results are means ± SEM of four 
determinations. ** P < 0.005; (b) Representative pictures of dying H9c2 cells exposed to 
different doses of palmitate. H9c2 cells were incubated for 24 h under control condition 
(CTRL), in the presence of different concentrations of palmitate (as shown in the picture), 
or palmitate plus 60 μM EPA.  
(a) 
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Figure 2. Cont. 
 
(b) 
3.2. Protective Effect of EPA on Palmitate-Induced Apoptosis 
In order to determine whether the observed reduction in viability of palmitate-treated 
cardiomyoblasts was due to apoptosis, H9c2 cells were treated with palmitate and caspase activity or 
TUNEL assay were used as markers of apoptosis. 
Figure 3a shows that after 24 h treatment with palmitate, caspase activity was increased about  
3 times compared to control cultures. Figure 3a also shows that EPA treatment did not affect the basal 
caspase-3 activity, but abolished the caspase-3 activation due to palmitate.  
Figure 3. Effect of EPA on apoptosis of H9c2 cardiomyoblasts exposed to palmitate. 48 h 
after plating H9c2 cells were incubated for 24 h with or without 500 µM palmitate in the 
presence or absence of 60 µM EPA. Cells were then collected for subsequent analysis.  
(a) The cells were assayed for caspase activity hydrolyzing the peptide sequence DEVD 
(DEVDase activity). The data are means ± SEM of four determinations. *** P < 0.001.  
(b) DNA fragmentation was determined by the quantitative assay of apoptotic cells 
(TUNEL assay). The data are means ± SEM of three determinations. ** P < 0.005. 
(a) (b) Nutrients 2012, 4  84 
 
 
The antiapoptotic effect of EPA was also evident from its ability to counteract DNA fragmentation 
in H9c2 cells exposed to palmitate, as determined by TUNEL assay (Figure 3b). These results show 
that the treatment with EPA counteracts the main biochemical markers of apoptosis such as the 
activation of caspases and the DNA fragmentation triggered by palmitate, thus suggesting that EPA 
may exert a protective effect in H9c2 cardiomyoblasts by preventing apoptotic programs.  
3.3. Palmitate Treatment Induces Autophagy in H9c2 Cardiac Cells: Effect of EPA 
The process of autophagosome formation depends on several autophagy proteins. SDS-PAGE and 
immunoblotting permit to detect endogenous LC3 as two bands: one represents LC3 I, which is the 
cytosolic form, and the other LC3 II, which is conjugated with phosphatidylethanolamine, and is 
membrane bound in autophagosomes [23]. 
In our experimental conditions we found that palmitate induced autophagy. In fact, as shown in 
Figure 4a, when H9c2 cardiomyoblasts were treated for 4 h with palmitate, a strong increase in the 
expression of LC3-II, an indicator of autophagosome formation, was observed (lane 3). This effect was 
completely prevented when EPA was added to the cells together with palmitate (lane 4). Quantification 
of the bands by densitometry is also shown (Figure 4b). 
Figure 4. Effect of palmitate and EPA on H9c2 autophagy. (a) 48 h after plating H9c2 
cells were incubated for 4 h with or without 500 µM palmitate in the presence or the 
absence of 60 µM EPA. Cell extracts were prepared and analyzed by Western blotting for 
cleavage of LC3 protein; GAPDH was used as internal control; (b) Densitometric analysis 
on immunoblots of six independent experiments was performed. *** P < 0.001; * P < 0.05. 
(a) (b) 
In order to determine whether autophagy plays a role in the induction of apoptosis under   
our experimental conditions, we treated cell cultures with the specific autophagy inhibitor   
3-methyladenine (3-MA). 
Figure 5a shows that the treatment of H9c2 cultures with 3-MA significantly prevented   
palmitate-induced autophagy, evidenced by a decreased expression of protein LC3-II. 
Figure 5b,c also show that palmitate-induced cell death, as indicated by Trypan Blue exclusion 
method or caspase activation, was not significantly modified in the presence of 3-MA, thus suggesting 
that autophagy might not be involved in the execution of apoptosis in these cells. Nutrients 2012, 4  85 
 
 
Figure 5. Effect of autophagy inhibition on cell death induced by palmitate. (a) 48 h after 
plating, H9c2 cells were incubated for 4 h with or without 500 µM palmitate in the 
presence or the absence of 10 µM 3-MA. Cell extracts were prepared and analyzed by 
Western blotting for cleavage of LC3 protein; GAPDH was used as internal control;   
(b,c) The cells exposed to 500 µM palmitate for 24 h in presence or absence of 10 μM 3-MA 
were assayed for caspase activity and Trypan Blue exclusion. Results are means ± SEM of 
three determinations. 
(a) 
(b) (c) 
4. Discussion  
Maintenance of cell viability is critically important, especially in myocytes, since their viability 
determines cardiac performance which, when impaired, leads to heart failure. Of the various inducers 
of cell death, saturated fatty acids have been recently reported to induce apoptosis in many different 
cell types [9,24], while EPA is believed to have a protective action against cardiovascular diseases, 
particularly coronary artery diseases [6]. 
Experimental evidence has shown that high levels of circulating saturated fatty acids are associated 
with coronary artery disease and cardiac dysfunction. In particular the accumulation of saturated   
fatty acids in the heart has been proposed to play a role in the development of heart failure and 
cardiomyopathy [3,4]. Clinical data show a correlation between fatty acid plasma level and 
cardiovascular disease, and several studies partially explained mechanisms by which saturated fatty 
acids directly induce lipotoxicity. 
In the present paper we showed that H9c2 cells exposed to palmitate display a reduced viability and 
an increase in caspase activation and DNA fragmentation, the main biochemical markers of apoptosis. 
The palmitate-induced damage can be related with overproduction of ceramides that release cytotoxic Nutrients 2012, 4  86 
 
 
free radicals and cytochrome c from the mitochondria, thus provoking apoptotic cell death [25,26]. 
Moreover palmitic acid can alter the levels of the cardiomyocyte cardiolipin, an important component 
of mitochondrial inner membrane [27]. It has also been reported that ischemic events promote fatty 
acid flux to the cardiac cells, increasing oxidative stress and contributing to cardiomyocyte damage [28].  
Numerous epidemiologic and observational studies report beneficial effects of n-3 PUFAs in the 
primary prevention, coronary artery disease and post-myocardial infarction, sudden cardiac death, 
heart failure and atherosclerosis [5,29]. However, their role in cardiac arrhythmias is still controversial. 
Some publications, in fact, supported a pro-arrhythmic effect of n-3 fatty acids [30–32], whereas many 
studies suggest that the modulation of ion channels exerted by PUFAs in animal models [22] would 
lead them to have anti-arrhythmic effects. 
Although PUFAs have an overall clinical protective role in cardiac patients, whether n-3 fatty acids 
exert direct effects on cardiac cell life has not been elucidated, in particular when it is challenged by 
noxious stimuli, such as following ingestion of diets too high in saturated fatty acid, during 
atherosclerosis, myocardial ischemia and heart failure. 
Our results showed a protective effect of EPA against palmitate-induced apoptosis and are 
consistent with other studies performed in different cell types [33]. In particular it has been recently 
reported that EPA supplementation protected rat neonatal cardiomyocytes against palmitate-induced 
apoptosis via the implication of several mitochondrial elements such as the translocation of Bax to the 
mitochondria and the release of cytochrome c [9]. 
According to recent studies, autophagy has emerged as a physiological process implicated in a wide 
variety of pathological conditions. In the presence of ample nutrient supply, anabolic reactions 
predominate within the cell and autophagy is maintained at low levels, those critical for normal 
cellular homeostasis and survival [34]. At the present new evidence suggests that autophagy can have a 
dual role in the heart. This process is rapidly activated in cardiac myocytes in response to a starvation 
period [35]. Upregulation of autophagy also occurs in the presence of external stressors, such as 
hormonal imbalance, hypoxia, oxidative stress and mitochondrial dysfunction [36–38]. Moreover, 
enhanced levels of autophagy are observed in certain clinically important circumstances, including 
neurodegenerative disorders, microbial invasion and cardiovascular diseases [12,13,39]. In particular, 
cardiac hypertrophy and the transition from hypertrophy to heart failure are modulated by an 
autophagic machinery [36]. 
In our experimental model we found that palmitate induces autophagy. This result prompted us to 
suggest that in palmitate-treated H9c2 cells, both apoptosis and autophagy can act as partners to induce 
cell death in a coordinated and cooperative manner, as shown in other experimental models [15]. The 
treatment with EPA showed an evident protective effect against palmitate induced toxicity, but it also 
prevented autophagy induction as well as apoptotic cell death. On the other hand, in a preliminary 
experiment with the autophagy inhibitor 3-MA, a significant cause-effect relationship between the two 
events was not observed. 
Although a direct and exclusive relationship between autophagy and apoptosis induction following 
treatment with palmitate might not exist, we cannot exclude that autophagy inhibition by EPA could be 
involved in potentiating the clear protective effect against palmitic acid-induced cell death and 
apoptosis in this cell model.  
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5. Conclusions 
In the present study we have evidenced that palmitic acid produces a cytotoxic effect on H9c2 
cardiomyoblasts and induces cell death by apoptosis. Interestingly, these effects are preceded and 
paralleled by an evident appearance of autophagy. The presence of EPA in the culture medium is able 
to counteract the pro-apoptotic and pro-autophagic effect of palmitate, so exerting a protective action 
in H9c2 cells. A full understanding of the multifaceted relationship between apoptosis and autophagy 
will be critical for the assessment of novel approaches for the treatment of cardiomyocyte injury 
associated with myocardial apoptosis. Detailing the molecular mechanisms of the process is of 
importance in order to then identify therapeutic targets that can be used to address cardiac disease. In 
conclusion, these findings provide further insight as to the cardiotoxic effect of saturated fatty acids 
and give important clinical implications regarding the positive role of n-3 PUFAs in reducing the risk 
of cardiovascular diseases related to cardiac cell death. 
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